-
Ariadne Solutions
Immunogenicity and Bioassay Summit – REM Software Demo and Presentations
/ Events / 0 commentsJoin us for the demonstration of the prototype of an automated software tool for determining cut point using Random Effects Model. Additionally, Dr. Stephanie Pasas-Farmer will be presenting at Bioassay Summit as well as co-presenting with Dr. Cheikh Kane from KCAS at Immunogenicity Summit.
4 -
Ariadne Solutions
Ariadne Software Receives SOC 2 Type 1 Attestation for its Information Security Management System
/ News / 0 commentsAriadne Software® is committed to maintaining the highest levels of security and data integrity for its customers. On this journey of security and compliance, Ariadne has reached another milestone of ISO/IEC 27001:2013 certification for its information security management system. The ISO 27001 guidance is designed to ensure confidentiality, integrity, and availability of an organization’s and its customers’ data by investing in its people, processes, and technologies.
-
Ariadne Solutions
Security and Compliance at Ariadne (and What it Means for your Data Security and Compliance Needs) Part – 1
/ Blog / 0 commentsWith so much of our personal and professional lives conducted online and in the cloud, data security and privacy is always one of the first questions we get asked at Ariadne Software. In Part 1 of this blog series, learn about the principles of security for SaaS programs in the pharmaceutical industry and the security measures we have implemented to ensure the highest level of safety and compliance with our client’s data.
-
Ariadne Solutions
AAPS e-Chalk Talk: “Answering Frequently Asked Questions Around Challenges When Using qPCR, ddPCR and NGS in Regulated Studies for Cell and Gene Therapy Products”
/ Events / 0 commentsIn April 2022, we discussed the role of molecular testing platforms, such as qPCR, ddPCR and NGS in enabling discovery and development of cell and gene therapy products. These technologies were recently introduced to bioanalysis of cell and gene therapy products, resulting in many unanswered questions on the appropriate use of these technologies in the field of bioanalysis, especially due to the lack of prescriptive guidance. We will use a redacted and anonymized qPCR case study to answer some of the questions that frequently come up.
